Cidara's Once-Weekly Antifungal Gets Phase III Boost From Mundipharma

Mundipharma is to provide financial support and development expertise for Cidara’s Phase III clinical studies of its once-weekly echinocandin antifungal for serious infections, in return for ex-US and ex-Japanese marketing rights.  

Mold
Aspergillus can cause fungal infections in patients • Source: Shutterstock

Mundipharma International Corp. Ltd.’s support of late-stage clinical studies for the once-weekly intravenous echinocandin antifungal, rezafungin, will be transformational for the San Diego, CA-based biotech, Cidara Therapeutics Inc. Inc., under a strategic collaboration between the two companies announced on 3 September and valued at $568m plus royalties.

Mundipharma is expected to make $42m available in near-term funding to support the ongoing global Phase III ReSTORE study of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category